Walling J
Invest New Drugs. 2005; 24(1):37-77.
PMID: 16380836
DOI: 10.1007/s10637-005-4541-1.
Bertino J, Silber R, Freeman M, ALENTY A, Albrecht M, GABRIO B
J Clin Invest. 1963; 42:1899-907.
PMID: 14090749
PMC: 289477.
DOI: 10.1172/JCI104875.
Grem J, Voeller D, Geoffroy F, Horak E, Johnston P, Allegra C
Br J Cancer. 1994; 70(6):1075-84.
PMID: 7981057
PMC: 2033700.
DOI: 10.1038/bjc.1994.451.
Varshavsky A
Proc Natl Acad Sci U S A. 1981; 78(6):3673-7.
PMID: 6943571
PMC: 319633.
DOI: 10.1073/pnas.78.6.3673.
Robertson S, Ling V, Stanners C
Mol Cell Biol. 1984; 4(3):500-6.
PMID: 6144041
PMC: 368728.
DOI: 10.1128/mcb.4.3.500-506.1984.
Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates.
Hryniuk W, Bertino J
J Clin Invest. 1969; 48(11):2140-55.
PMID: 5259150
PMC: 297468.
DOI: 10.1172/JCI106181.
[Effect and istribution of methotrexate in the human organism during leukemia treatment].
Wilmanns W, Martin H
Klin Wochenschr. 1968; 46(6):281-96.
PMID: 5245556
DOI: 10.1007/BF01738686.
[Dihydrofolate reductase and thymidine kinase in the bone marrow under the influence of folic acid antagonists].
Wilmanns W
Klin Wochenschr. 1967; 45(19):987-94.
PMID: 5245308
DOI: 10.1007/BF01746131.
A haematological study of patients receiving long-term treatment with trimethoprim and sulphonamide.
Jenkins G, Hughes D, Hall P
J Clin Pathol. 1970; 23(5):392-6.
PMID: 4920413
PMC: 476778.
DOI: 10.1136/jcp.23.5.392.
[Determination, properties and inhibition of thymidilate synthetase in immature myeloid blood and bone marrow cells].
Wilmanns W, Neef V
Blut. 1971; 22(6):305-19.
PMID: 4397704
DOI: 10.1007/BF01632020.
Rat folic acid reductase activity during the perinatal period, in newborns, and after trimethoprim administration.
Schulz R
Naunyn Schmiedebergs Arch Pharmacol. 1972; 274(3):229-37.
PMID: 4262779
DOI: 10.1007/BF00501932.
The variability of individual tolerance to methotrexate in cancer patients.
Hansen H, SELAWRY O, HOLLAND J, MCCALL C
Br J Cancer. 1971; 25(2):298-305.
PMID: 4256007
PMC: 2008449.
DOI: 10.1038/bjc.1971.38.
[Estimation of tumor sensitivity in vitro. I. Comparative studies with the Jensen sarcoma in vivo and in vitro after 1-hour-incubation].
Seidel H, WEGNER L
Z Krebsforsch. 1969; 72(2):105-18.
PMID: 4182038
The development of resistance to methotrexate in a mouse melanoma cell line. I. Characterisation of the dihydrofolate reductases and chromosomes in sensitive and resistant cells.
Bostock C, Clark E, Harding N, Mounts P, Tyler-Smith C, Van Heyningen V
Chromosoma. 1979; 74(2):153-77.
PMID: 510081
DOI: 10.1007/BF00292270.
Clinical pharmacokinetics of methotrexate.
Shen D, AZARNOFF D
Clin Pharmacokinet. 1978; 3(1):1-13.
PMID: 346283
DOI: 10.2165/00003088-197803010-00001.